{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:47:43Z","timestamp":1785422863765,"version":"3.56.0"},"reference-count":30,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["BJPsych open"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec id=\"S2056472426120419_as1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The true incidence of treatment-resistant schizophrenia (TRS) remains uncertain, largely because earlier studies relied on heterogeneous definitions and retrospective assessments. The Treatment Response and Resistance in Psychosis (TRRIP) consensus established standardised diagnostic criteria, but these have rarely been applied prospectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2056472426120419_as2\">\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To estimate the incidence of TRS prospectively by using operationalised TRRIP criteria within a large community-based trial, and to examine whether baseline demographic or clinical variables predict its emergence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2056472426120419_as3\">\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We applied TRRIP criteria to 1334 participants with chronic schizophrenia enrolled in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. TRS was defined as persistent symptoms and functional impairment following two adequate antipsychotic trials, each meeting TRRIP thresholds for duration, dose and adherence. Incidence was estimated with bootstrap resampling, and logistic regression examined associations between baseline variables and TRS onset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2056472426120419_as4\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1334 participants, 782 (58.6%) met TRRIP absolute symptom thresholds at baseline; 77 (9.8%) fulfilled full criteria for TRS during follow-up. The incidence rate was 5.68 per 100 person-years (95% CI 4.51\u20137.02) overall and 9.20 per 100 person-years (95% CI 7.43\u201311.39) among above-threshold participants. Higher baseline Positive and Negative Syndrome Scale positive and negative subscale scores and greater global illness severity were associated with TRS, although predictive performance was poor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S2056472426120419_as5\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This first prospective application of TRRIP criteria to a randomised trial data-set provides robust estimates of TRS incidence. Routine clinical and demographic variables have limited predictive value, supporting the need for longitudinal, biologically informed studies that use TRRIP-aligned frameworks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1192\/bjo.2026.12041","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:41:07Z","timestamp":1784533267000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":0,"title":["The prospective incidence of treatment-resistant schizophrenia: analysis of the CATIE trial using the TRRIP consensus"],"prefix":"10.1192","volume":"12","author":[{"given":"Dan W.","family":"Joyce","sequence":"first","affiliation":[{"name":"University of Liverpool"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8556-090X","authenticated-orcid":false,"given":"Sajitha","family":"Nair","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0381np041","id-type":"ROR","asserted-by":"publisher"}],"name":"Kent and Medway NHS and Social Care Partnership Trust"},{"id":[{"id":"https:\/\/ror.org\/00xkeyj56","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Kent"},{"id":[{"id":"https:\/\/ror.org\/049p9j193","id-type":"ROR","asserted-by":"publisher"}],"name":"Kent and Medway Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3178-3920","authenticated-orcid":false,"given":"Alexis E.","family":"Cullen","sequence":"additional","affiliation":[{"name":"King\u2019s College London"},{"name":"Karolinska Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Bressan","sequence":"additional","affiliation":[{"name":"King\u2019s College London"},{"name":"Federal University of Sao Paulo"},{"name":"Federal University of Sao Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhi","family":"Shergill","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0381np041","id-type":"ROR","asserted-by":"publisher"}],"name":"Kent and Medway NHS and Social Care Partnership Trust"},{"id":[{"id":"https:\/\/ror.org\/049p9j193","id-type":"ROR","asserted-by":"publisher"}],"name":"Kent and Medway Medical School"},{"name":"King\u2019s College London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"S2056472426120419_ref7","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291717000435"},{"key":"S2056472426120419_ref5","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.4.544"},{"key":"S2056472426120419_ref13","first-page":"663","article-title":"The Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with schizophrenia","volume":"65","author":"Correll","year":"2020","journal-title":"Can J Psychiatry"},{"key":"S2056472426120419_ref2","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"S2056472426120419_ref16","volume-title":"Structured Clinical Interview for DSM-FV Axis I Disorder Administration Booklet","author":"First","year":"1994"},{"key":"S2056472426120419_ref23","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"2004"},{"key":"S2056472426120419_ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0241-z"},{"key":"S2056472426120419_ref9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2021.61"},{"key":"S2056472426120419_ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"S2056472426120419_ref30","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030895"},{"key":"S2056472426120419_ref14","first-page":"e12","article-title":"European Psychiatric Association guidance on the assessment and management of treatment resistant schizophrenia","volume":"63","author":"Kane","year":"2020","journal-title":"Eur Psychiatry"},{"key":"S2056472426120419_ref29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13010085"},{"key":"S2056472426120419_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(88)90038-8"},{"key":"S2056472426120419_ref25","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-19425-7"},{"key":"S2056472426120419_ref12","first-page":"482","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 3: update 2019 on the treatment of acute schizophrenia and the management of treatment resistance","volume":"21","author":"Hasan","year":"2020","journal-title":"World J Biol Psychiatry"},{"key":"S2056472426120419_ref4","first-page":"1","article-title":"Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders","volume":"39","year":"2005","journal-title":"Aust N Z J Psychiatry"},{"key":"S2056472426120419_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2007.04.001"},{"key":"S2056472426120419_ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01720.x"},{"key":"S2056472426120419_ref21","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"S2056472426120419_ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234121"},{"key":"S2056472426120419_ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01308.x"},{"key":"S2056472426120419_ref22","first-page":"1","article-title":"mice: multivariate imputation by chained equations in R","volume":"45","author":"Van Buuren","year":"2011","journal-title":"J Stat Softw"},{"key":"S2056472426120419_ref28","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S503494"},{"key":"S2056472426120419_ref27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1478625"},{"key":"S2056472426120419_ref8","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716002014"},{"key":"S2056472426120419_ref20","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbv167"},{"key":"S2056472426120419_ref11","volume-title":"Psychosis and Schizophrenia in Adults: Prevention and Management","year":"2014"},{"key":"S2056472426120419_ref26","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5941"},{"key":"S2056472426120419_ref10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050503"},{"key":"S2056472426120419_ref3","volume-title":"Schizophrenia","author":"Weinberger","year":"2011"}],"container-title":["BJPsych Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2056472426120419","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:41:10Z","timestamp":1784533270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2056472426120419\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["S2056472426120419"],"URL":"https:\/\/doi.org\/10.1192\/bjo.2026.12041","relation":{},"ISSN":["2056-4724"],"issn-type":[{"value":"2056-4724","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"\u00a9 The Author(s), 2026. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike licence (https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the same Creative Commons licence is used to distribute the re-used or adapted article and the original article is properly cited. The written permission of Cambridge University Press or the rights holder(s) must be obtained prior to any commercial use.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e191"}}